TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Best corrected distance visual acuity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in breathlessness intensity ratings
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Changes in Motor Function (Jebsen-Taylor Task)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in Fugl-Meyer Assessment (FMA) Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to Persistent Atrial Fibrillation/Atrial Tachycardia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Modified Bristol Stool Form score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Extremity pain measured by VAS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Positive yields in Crohn's capsule
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: PsARC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Physician Global Assessment for Psoriasis and Psoriasis Target Lesion Assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Liver triglyceride concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage change in LDL-C concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of Participants with complications
Endpoint domain: Adverse events/effects
Primary endpoint: Primary dysfunction of liver graft
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Percentage Change From Baseline in SELENA SLEDAI Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to First Mild/Moderate or Severe SLE Flare
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 30-day secondary patency rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Outcome of gemtuzumab ozogamicin-based therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in marginal peri-implant bone loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Prevalence of Cryptosporidium
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Insulin sensitivity/resistance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: improvement in working memory
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: improvement in executive function
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Presence or absence of peripheral arterial disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Change from Baseline function at 1 month
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change from Baseline pain at 1 month
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Area under the concentration time curve (AUC) from 0 to 8 hours (AUC0-8)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants completing a follow-up colonoscopy procedure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change in Decisional Conflict Scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: maximum tolerated dose (MTD) of IV MSCs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the curve (AUC) 0-24h
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Area under the curve (AUC) 0-6h
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Maximum concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Time to maximum concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Chronic headache
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Chronic back pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of cryptococcal antigenaemia and antigenuria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Serum concentrations of the analyte
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Amount of analyte excreted in urine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum-tolerated Dose of Veliparib
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants Observed to Have Unacceptable Toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Endoscopic efficacy of ustekinumab treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical efficacy of ustekinumab treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of rapid infant weight gain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Prevalence of overweight in infants
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Glycogen Storage Assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Spontaneous urinary flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Biomechanical properties of urethra
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Cystometri
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Uretal pressure profile
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: HBV virologic response (HBV DNA < 2,000 IU/mL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Number of infants with ductus closure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Efficacy as determined by de novo ureagenesis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Numerical Rating Leg Pain Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevention of CRBSI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Clinical tolerance assessed by digestive symptomatology
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Biological tolerance assessed by nutritional markers and malabsorption markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Diagnostic factor of Shear Wave Elastography
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in disease severity over time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pharmacokinetics of memantine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pharmacokinetics of RO5313534
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC (0-t) of total drug-related material in blood and plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax of GSK1349572 in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent recovery of total radiocarbon in urine and feces
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total Ghrelin Level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Acylated Ghrelin Level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Number of contaminated water bodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Work and Social Adjustments Scale (WSAS)
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Mean Change From Baseline in Total Daily OFF Time (Hours)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in anthropometric indices
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Degree of appetite
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Amount of food intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in EEQ Score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: SARS-CoV-2 prevalence
Endpoint domain: Adverse events/effects
Primary endpoint: Recovery rate of SAM, SUW and IAP Grade III,IV
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Case fatality rate of treated severely malnourished children
Endpoint domain: Mortality/survival
Primary endpoint: Prevalence of severe malnutrition
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Level of agreement between ultrasound and evacuation proctography
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Turn Around Time
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Tumor Necrosis Factor alpha expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Participant's skills uptake
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Improvement in IS use compliance
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: number of 3-months periods with remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical practice adherence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in plasma GLP-1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Number of Participants Ranking Intervention as Acceptable
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Percent Change From Baseline in Total Hip Bone Mineral Density
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Focal electroretinogram (FERG)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Psychosis Schedule for Affective Disorders in Schizophrenia - Delusional Item
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Hemoglobin Rise
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Preference for Rituximab SC over IV at Cycle 6
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Preference for Rituximab SC over IV at Cycle 8
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Total Number of Consecutive Bleeding-free Days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity and specificity values for FEES
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Word reading
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pseudo-word reading
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Freedom From Headache
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Satisfaction with reproductive discussions
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Comfort with reproductive discussions
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Satisfaction with MyPath
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: 6 Minutes Walking Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safeness of autologous bone marrow derived stem cells
Endpoint domain: Adverse events/effects
Primary endpoint: Security of the current attachment
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Security of the early attachment
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Mentalization
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Quality of early relationship
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Diagnosis of NSF
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in portal pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Change in average daily frequency of hot flashes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Primary Patency at 12 Months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety-related Event at 12 Months
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Systolic blood pressure below 90 mmHg
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of Proteins Expressed Differently
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of Pain on Function (PoF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median Time to First Cardiovascular Event
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Predictive and prognostic value of mutations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in Modified Ashworth Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Global Impression of Change Scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of Participants With Confirmed Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of HbA1c From Baseline at Week 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Disease Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Arterial Enhancement, Per Lesion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Progression-free Survival (PFS) as Assessed by the Investigator
Endpoint domain: Mortality/survival
Primary endpoint: Progression-free Survival (PFS) as Assessed by an Independent Radiologist
Endpoint domain: Mortality/survival
Primary endpoint: Neonatal cardiovascular status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Disease progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change in shoulder internal rotation and horizontal adduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Peak Pruritus Numerical Rating Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Potentially Clinically Significant Laboratory Abnormalities: Hematological Parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Number of Participants With Potentially Clinically Significant Laboratory Abnormalities: Biochemical Parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Value variations of hormones involved in phosphate homeostasis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Area under the concentration time curve [AUC]
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to maximum plasma concentration [Tmax]
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Who Could Tolerate Twice Daily Oxytocin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vascular Endothelial Function (Flow mediated dilation or FMD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Energy cost of domestic physical activities
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in number of CTCs and CECs in blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Percentage Change in Psoriasis Area and Severity Index (PASI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Self-reported pain scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: 12 Month Retention Rate
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Numeric Rating Scale (NRS) Pain scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of subjects reporting serious adverse events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of subjects reporting serious adverse events (SAEs) considered related to vaccination
Endpoint domain: Adverse events/effects
Primary endpoint: Number of subjects reporting severe (Grade 3) laboratory Adverse Events (AE) considered related to vaccination
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Plaque Accumulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of mature oocytes recovered and cryopreserved
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Percentage Change in Total Partial Seizure Frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Composite of death
Endpoint domain: Mortality/survival
Primary endpoint: Acute radiation-induced events
Endpoint domain: Adverse events/effects
Primary endpoint: Late radiation-induced effects
Endpoint domain: Adverse events/effects
Primary endpoint: PDE10A Occupancy of Brain Regions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in frequency of recording of nutritional diagnoses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Cognitive function 6 months after hospital discharge
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Diffusion capacity 6 months after hospital discharge
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Incidence of post myocarditis findings in MRI of the heart
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Assessment of vulnerable plaque
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Motor recovery assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Calories purchased
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain subscale of WOMAC LK 3.1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cumulative incidence of locoregionally recurrent colon cancer
Endpoint domain: Mortality/survival
Primary endpoint: Overall survival of patients with locoregionally recurrent colon cancer
Endpoint domain: Mortality/survival
Primary endpoint: Prevalence of Lysosomal Acid Lipase deficiency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Manual Dexterity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Investigator's global assessment
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Labor Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Magnitude of [18F]Fluciclatide Uptake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Magnitude of [18F]Fluciclatide Retention
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Levels of αvβ3 Integrin Expression in Tumors
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Response on MRI using the RANO Criteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Knee disorder recovery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change from baseline functional magnetic resonance imaging
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: early postoperative biliary fistula
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: HPA responses to stress
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Presence of cost discussion
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change on functional connectivity of visual resting network
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change on signal strength of the visual cortex activation by visual tasking state fMRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change on anatomical Connectivity of the posterior visual pathway
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Sensitivity of extended urine cultures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes